Balchem Stock Forecast, Price & News

+0.67 (+0.50 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume106,939 shs
Average Volume75,356 shs
Market Capitalization$4.38 billion
P/E Ratio49.77
Dividend Yield0.43%
30 days | 90 days | 365 days | Advanced Chart
Receive BCPC News and Ratings via Email

Sign-up to receive the latest news and ratings for Balchem and its competitors with MarketBeat's FREE daily newsletter.

Balchem logo

About Balchem

Balchem Corp. provides marketing of specialty performance ingredients and products. It operates through the following segments: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products and Industrial Products. The Human Nutrition and Health segment supplies ingredients in the food and beverage industry, providing customized solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems, and cereal systems. The Animal Nutrition and Health segment comprises nutritional products derived from microencapsulation and chelation technologies in addition to basic choline chloride. The Specialty Products segment offers Ethylene oxide for the health care industry. The Industrial Products segment refers to certain derivatives of choline chloride which manufactured and sold into industrial applications as a component for hydraulic fracturing of shale natural gas wells. The company was founded in January 1967 and is headquartered in New Hampton, NY.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.12 out of 5 stars

Basic Materials Sector

44th out of 302 stocks

Chemicals & Allied Products Industry

6th out of 11 stocks

Analyst Opinion: 1.5Community Rank: 4.5Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Balchem (NASDAQ:BCPC) Frequently Asked Questions

Is Balchem a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Balchem in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Balchem stock.
View analyst ratings for Balchem
or view top-rated stocks.

What stocks does MarketBeat like better than Balchem?

Wall Street analysts have given Balchem a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Balchem wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Balchem?

Balchem saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 403,900 shares, a decline of 28.9% from the June 15th total of 567,700 shares. Based on an average daily trading volume, of 115,900 shares, the days-to-cover ratio is presently 3.5 days. Currently, 1.3% of the shares of the company are sold short.
View Balchem's Short Interest

When is Balchem's next earnings date?

Balchem is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Balchem

How were Balchem's earnings last quarter?

Balchem Co. (NASDAQ:BCPC) released its quarterly earnings data on Friday, July, 30th. The basic materials company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.11. Balchem had a net margin of 12.35% and a trailing twelve-month return on equity of 13.35%.
View Balchem's earnings history

How has Balchem's stock been impacted by Coronavirus (COVID-19)?

Balchem's stock was trading at $89.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BCPC stock has increased by 51.1% and is now trading at $134.89.
View which stocks have been most impacted by COVID-19

How often does Balchem pay dividends? What is the dividend yield for Balchem?

Balchem declared an annual dividend on Thursday, December 17th. Shareholders of record on Monday, December 28th will be paid a dividend of $0.58 per share on Friday, January 22nd. This represents a dividend yield of 0.5%. The ex-dividend date is Thursday, December 24th. This is a boost from Balchem's previous annual dividend of $0.26.
View Balchem's dividend history

Is Balchem a good dividend stock?

Balchem pays an annual dividend of $0.58 per share and currently has a dividend yield of 0.43%. Balchem does not yet have a strong track record of dividend growth. The dividend payout ratio of Balchem is 17.47%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Balchem will have a dividend payout ratio of 13.88% next year. This indicates that Balchem will be able to sustain or increase its dividend.
View Balchem's dividend history.

What price target have analysts set for BCPC?

2 equities research analysts have issued 12 month target prices for Balchem's shares. Their forecasts range from $140.00 to $145.00. On average, they expect Balchem's share price to reach $142.50 in the next twelve months. This suggests a possible upside of 5.6% from the stock's current price.
View analysts' price targets for Balchem
or view top-rated stocks among Wall Street analysts.

Who are Balchem's key executives?

Balchem's management team includes the following people:
  • Theodore L. Harris, Chairman, President & Chief Executive Officer
  • Martin Bengtsson, Chief Financial Officer & Treasurer
  • Jeff McCartney, Senior Director-Information Technology
  • Michael Sestrick, Chief Technology Officer
  • James Hyde, SVP & General Manager-Human Health & Nutrition

What is Dino A. Rossi's approval rating as Balchem's CEO?

15 employees have rated Balchem CEO Dino A. Rossi on Dino A. Rossi has an approval rating of 85% among Balchem's employees.

Who are some of Balchem's key competitors?

What other stocks do shareholders of Balchem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Balchem investors own include Ecolab (ECL), CVS Health (CVS), AbbVie (ABBV), Johnson & Johnson (JNJ), Lowe's Companies (LOW), Altria Group (MO), NVIDIA (NVDA), AT&T (T), Analog Devices (ADI) and Bristol-Myers Squibb (BMY).

What is Balchem's stock symbol?

Balchem trades on the NASDAQ under the ticker symbol "BCPC."

Who are Balchem's major shareholders?

Balchem's stock is owned by a variety of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.26%), Davy Global Fund Management Ltd (0.17%), Alliancebernstein L.P. (0.16%), Bath Savings Trust Co (0.12%), State of Alaska Department of Revenue (0.07%) and Cardinal Capital Management (0.06%). Company insiders that own Balchem stock include David F Ludwig and Scott C Mason.
View institutional ownership trends for Balchem

Which institutional investors are selling Balchem stock?

BCPC stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Bath Savings Trust Co, Oregon Public Employees Retirement Fund, and Cardinal Capital Management.
View insider buying and selling activity for Balchem
or view top insider-selling stocks.

Which institutional investors are buying Balchem stock?

BCPC stock was purchased by a variety of institutional investors in the last quarter, including Davy Global Fund Management Ltd, Carderock Capital Management Inc., Alliancebernstein L.P., and State of Alaska Department of Revenue.
View insider buying and selling activity for Balchem
or or view top insider-buying stocks.

How do I buy shares of Balchem?

Shares of BCPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Balchem's stock price today?

One share of BCPC stock can currently be purchased for approximately $134.89.

How much money does Balchem make?

Balchem has a market capitalization of $4.38 billion and generates $703.64 million in revenue each year. The basic materials company earns $84.62 million in net income (profit) each year or $3.32 on an earnings per share basis.

How many employees does Balchem have?

Balchem employs 1,342 workers across the globe.

When was Balchem founded?

Balchem was founded in 1967.

What is Balchem's official website?

The official website for Balchem is

Where are Balchem's headquarters?

Balchem is headquartered at 52 Sunrise Park Road, NEW HAMPTON NY, 10958.

How can I contact Balchem?

Balchem's mailing address is 52 Sunrise Park Road, NEW HAMPTON NY, 10958. The basic materials company can be reached via phone at (845) 326-5600 or via email at [email protected]

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.